Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Total Liabilities: 2011-2025

Historic Total Liabilities for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to $137.5 million.

  • Adma Biologics' Total Liabilities fell 13.37% to $137.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.5 million, marking a year-over-year decrease of 13.37%. This contributed to the annual value of $139.7 million for FY2024, which is 28.00% down from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Total Liabilities is $137.5 million, which was down 14.09% from $160.1 million recorded in Q2 2025.
  • Adma Biologics' Total Liabilities' 5-year high stood at $200.2 million during Q3 2022, with a 5-year trough of $121.2 million in Q2 2021.
  • In the last 3 years, Adma Biologics' Total Liabilities had a median value of $188.1 million in 2024 and averaged $172.8 million.
  • As far as peak fluctuations go, Adma Biologics' Total Liabilities surged by 50.58% in 2022, and later tumbled by 30.44% in 2025.
  • Quarterly analysis of 5 years shows Adma Biologics' Total Liabilities stood at $135.1 million in 2021, then soared by 45.46% to $196.5 million in 2022, then decreased by 1.28% to $194.0 million in 2023, then declined by 28.00% to $139.7 million in 2024, then dropped by 13.37% to $137.5 million in 2025.
  • Its last three reported values are $137.5 million in Q3 2025, $160.1 million for Q2 2025, and $137.2 million during Q1 2025.